Compounds > t-butyloxycarbonylaspartic acid alpha-benzyl ester
Page last updated: 2024-11-06

t-butyloxycarbonylaspartic acid alpha-benzyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

t-Butyloxycarbonylaspartic acid alpha-benzyl ester, also known as Boc-Asp(OBzl)-OH, is a protected amino acid derivative commonly used in peptide synthesis. It is synthesized by reacting aspartic acid with di-tert-butyl dicarbonate (Boc2O) to introduce the Boc protecting group, followed by esterification with benzyl alcohol. The Boc protecting group is known for its stability under mild acidic conditions and its ability to be easily removed under mild basic conditions, making it a valuable tool for selective deprotection in peptide synthesis. The benzyl ester group provides another point of protection for the carboxyl group of aspartic acid, allowing for selective deprotection at the alpha-amino group during peptide synthesis. The compound is important for its role in the synthesis of peptides containing aspartic acid residues, which are essential components of many biologically active peptides and proteins. t-Butyloxycarbonylaspartic acid alpha-benzyl ester is studied extensively in the field of peptide chemistry to develop new and efficient methods for peptide synthesis and to understand the structure-activity relationships of peptides and proteins.'
```

t-butyloxycarbonylaspartic acid alpha-benzyl ester: substrate for vitamin K-dependent carboxylase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1581888
CHEMBL ID1299590
SCHEMBL ID84710
SCHEMBL ID344669
MeSH IDM0108931
PubMed CID82036
CHEMBL ID1906597
SCHEMBL ID344670
MeSH IDM0108931

Synonyms (116)

Synonym
AC-15060
HMS2629N19
aspartic acid, n-carboxy-, 4-benzyl n-tert-butyl ester, l-
boc-asp(obzl)-oh
smr000313107
MLS000686264
(2s)-4-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]-4-oxobutanoic acid
n-tert-butoxycarbonyl-l-aspartic acid .beta.-benzyl ester
7536-58-5
(2s)-4-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]-4-oxobutanoic acid (non-preferred name)
STK014529
boc-asp(obzl)-oh, >=99.0% (sum of enantiomers, hplc)
4-benzyl n-boc-l-aspartate
4-benzyl n-(tert-butoxycarbonyl)-l-aspartate
n-(tert-butoxycarbonyl)-l-aspartic acid 4-benzyl ester
B1628 ,
n-boc-l-aspartic acid 4-benzyl ester
AKOS000491316
(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutanoic acid
NCGC00245870-01
n-alpha-t-boc-l-aspartic-beta-benzyl ester
CHEMBL1299590
AKOS015922891
boc-l-aspartic acid-4-benzyl ester
boc-l-aspartic acid 4-benzyl ester
AB00620016-07
M03266
SCHEMBL84710
SCHEMBL344669
(s)-2-t-butoxycarbonylamino-succinic acid 4-benzyl ester
boc-asp-(obzl)-oh
(s)-2-tert-butoxycarbonylamino-succinic acid 4-benzyl ester
boc-asp(bzl)-oh
n-(tert-butoxycarbonyl)aspartic acid-4-benzyl ester
boc-asp(obzl)
n-(t-butyloxycarbonyl)-l-aspartic acid 4-benzyl ester
boc-aspartic acid beta-benzyl ester
boc-l-asp(obn)-oh
boc-asp(obn)-oh
(2s)-4-(benzyloxy)-2-{[(tert-butoxy)carbonyl]amino}-4-oxobutanoic acid
boc-l-asp(obzl)-oh
n-(t-butoxycarbonyl)-l-aspartic acid 4-benzyl ester
(s)-4-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid
Q-101783
boc-l-asparticacid4-benzylester
n-((1,1-dimethylethoxy)carbonyl)-l-aspartic acid, 4-(phenylmethyl)ester
o-benzyl-n-(tert-butoxycarbonyl)-4-oxohomoserine #
l-aspartic acid, n-[(1,1-dimethylethoxy)carbonyl]-, 4-(phenylmethyl) ester
CS-0020431
n-alpha-t-butyloxycarbonyl-l-aspartic acid beta-benzyl ester
sr-01000084220
SR-01000084220-1
NCGC00245870-02
F14855
n-alpha-t-boc-l-aspartic acid beta-benzyl ester
(s)-4-(benzyloxy)-2-(tert-butoxycarbonylamino)-4-oxobutanoic acid
boc-l-aspartic acid b-benzyl ester
AS-14197
DTXSID40884402
EN300-204848
HY-Z0615
LQ5UR33F4Q
beta-benzyl n-tert-butoxycarbonylaspartate
t-butyloxycarbonylaspartic acid alpha-benzyl ester
n-tert-butoxycarbonyl-l-aspartic acid beta-benzyl ester
n-((1,1-dimethylethoxy)carbonyl)-l-aspartic acid, 4-(phenylmethyl) ester
einecs 231-406-8
4-benzyl hydrogen n-(tert-butoxycarbonyl)-l-aspartate
nsc 118538
nsc118538
aspartic acid, 4-benzyl n-tert-butyl ester, l-
l-aspartic acid,1-dimethylethoxy)carbonyl]-, 4-(phenylmethyl) ester
n-[(1, 4-(phenylmethyl) ester
n-tert-butoxycarbonyl-l-aspartic acid 4-benzyl ester
nsc-118538
MLS000778584 ,
2-tert-butoxycarbonylamino-succinic acid 4-benzyl ester
smr000415378
98482-77-0
AKOS003264158
NCGC00246511-01
4-(benzyloxy)-2-{[(tert-butoxy)carbonyl]amino}-4-oxobutanoic acid
147291-69-8
4-(benzyloxy)-2-(tert-butoxycarbonylamino)-4-oxobutanoic acid
boc-dl-aspartic acid 4-benzylester
A828481
2-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]-4-oxo-4-phenylmethoxybutanoic acid
2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxidanylidene-4-phenylmethoxy-butanoic acid
HMS2769A13
aspartic acid, n-[(1,1-dimethylethoxy)carbonyl]-, 4-(phenylmethyl) ester
FT-0629325
FT-0600678
SCHEMBL344670
SOHLZANWVLCPHK-UHFFFAOYSA-N
4-(benzyloxy)-2-[(t-butoxycarbonyl)amino]-4-oxobutanoic acid
CHEMBL1906597
4-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]-4-oxobutanoic acid
mfcd00065564
SR-01000312244-1
sr-01000312244
4-benzyloxy-2-(t-butoxycarbonyl-amino)-4-oxobutanoic acid
AS-52596
SY031262
SY017619
4-(benzyloxy)-2-{[(tert-butoxy)carbonyl]amino-4-oxobutanoic acid
4-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid
4-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoicacid
d-aspartic acid, n-[(1,1-dimethylethoxy)carbonyl]-, 4-(phenylmethyl)ester
P15386
PB42949
EN300-195389
B8JQ67EU7K
dl-aspartic acid, n-[(1,1-dimethylethoxy)carbonyl]-, 4-(phenylmethyl) ester
4-(phenylmethyl) hydrogen n-[(1,1-dimethylethoxy)carbonyl]aspartate
boc-dl-asp(obn)-oh
4-(benzyloxy)-2-([(tert-butoxy)carbonyl]amino)-4-oxobutanoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency50.11870.631035.7641100.0000AID504339
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
regulator of G-protein signaling 4Homo sapiens (human)Potency79.43280.531815.435837.6858AID504845
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
survival motor neuron protein isoform dHomo sapiens (human)Potency3.98110.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency0.12590.891312.067628.1838AID1487
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.54810.003245.467312,589.2998AID2517
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency6.30960.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.94 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		7.6730aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
cadmium
Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.		2.0310cadmium molecular entity;
zinc group element atom
2,2'-dipicolylamine
2,2'-dipicolylamine: structure in first source		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.4620
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.4620
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0310